Pentixapharm Holding AG (FRA:PTP) Total Liabilities: €9.02 Mil (As of Mar. 2026)


FRA:PTP Pentixapharm Holding AG FRA:PTP
20 GF Score
Price €2.20
! 2 Warning Signs
View Full Analysis

What is Pentixapharm Holding AG Total Liabilities?

Pentixapharm Holding AG FRA:PTP -4.35% 20 Total Liabilities is €9.02 Mil as of Mar. 2026. GuruFocus rates FRA:PTP with a GF Score™ of 20/100. The stock has 2 warning signs investors should review.

Pentixapharm Holding AG's Total Liabilities for the quarter that ended in Mar. 2026 was €9.02 Mil.

Pentixapharm Holding AG's quarterly Total Liabilities increased from Sep. 2025 (€6.24 Mil) to Dec. 2025 (€6.79 Mil) and increased from Dec. 2025 (€6.79 Mil) to Mar. 2026 (€9.02 Mil).

Pentixapharm Holding AG's annual Total Liabilities declined from Dec. 2023 (€24.92 Mil) to Dec. 2024 (€17.97 Mil) and declined from Dec. 2024 (€17.97 Mil) to Dec. 2025 (€6.79 Mil).

Pentixapharm Holding AG Total Liabilities Historical Data

* Premium members only.

The historical data trend for Pentixapharm Holding AG's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pentixapharm Holding AG Total Liabilities Chart

Pentixapharm Holding AG Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Total Liabilities
1.26 15.41 24.92 17.97 6.79

Pentixapharm Holding AG Quarterly Data
Dec21 Dec22 Dec23 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 10.13 10.07 6.24 6.79 9.02
FRA:PTP
20GF Score
Pentixapharm Holding AG FRA:PTP
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pentixapharm Holding AG Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Pentixapharm Holding AG's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=3.459+(0+3.328
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=6.79

Total Liabilities=Total Assets (A: Dec. 2025 )-Total Equity (A: Dec. 2025 )
=41.859-35.072
=6.79

Pentixapharm Holding AG's Total Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=2.944+(0+6.072
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=9.02

Total Liabilities=Total Assets (Q: Mar. 2026 )-Total Equity (Q: Mar. 2026 )
=41.168-32.152
=9.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of €9.02 Mil mean?
Pentixapharm Holding AG (FRA:PTP) has a Total Liabilities of €9.02 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Pentixapharm Holding AG and its competitors.
Is Pentixapharm Holding AG's Total Liabilities too high?
Pentixapharm Holding AG's current Total Liabilities is €9.02 Mil. Overall, Pentixapharm Holding AG has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Pentixapharm Holding AG's Total Liabilities compare to VRTX and REGN?
Pentixapharm Holding AG's Total Liabilities of €9.02 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Pentixapharm Holding AG and its competitors. Pentixapharm Holding AG's current Total Liabilities is €9.02 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pentixapharm Holding AG stock overvalued right now?
Pentixapharm Holding AG (FRA:PTP) has a current Total Liabilities of €9.02 Mil. The current Total Liabilities is €9.02 Mil. Pentixapharm Holding AG's overall GF Score™ is 20/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Pentixapharm Holding AG (FRA:PTP), the current Total Liabilities is €9.02 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Pentixapharm Holding AG Business Description

Other Exchanges PTP:GermanyPTPN:Austria
Address Robert-Rossle-Street 10, Berlin, DEU, 13125
Pentixapharm Holding AG is a clinical-stage biopharmaceutical company active in the field of research and development of radiopharmaceuticals for diagnostic and therapeutic applications. Radiopharmaceuticals are medical substances containing radioactive elements used in nuclear medicine to diagnose or treat diseases. Its clinical pipeline encompasses PentixaTher, a Yttrium-90 based therapeutic against non-Hodgkin lymphomas (NHL), and PentixaFor, a Gallium-68-based companion diagnostic. Its Pipeline products include: Pentixa Ther, PT-002, PentixaFor, PT-001, PentixaFor, PT-001, PT-00X, GT-001, GT-002, GT-005, GT-008, and GT-00X.
20GF Score

Get the complete analysis for FRA:PTP

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.20
Price